Giripladib is an indole-based inhibitor of cytosolic phospholipase A2 (cPLA2) that has been investigated for its potential in treating inflammatory conditions, including research into osteoarthritis and… Read more
Giripladib is an indole-based inhibitor of cytosolic phospholipase A2 (cPLA2) that has been investigated for its potential in treating inflammatory conditions, including research into osteoarthritis and breast cancer. This category includes high-quality reference standards of Giripladib, alongside a selection of its related impurities, metabolites, and stable isotope-labelled compounds. These materials are essential tools for pharmaceutical laboratories conducting rigorous analytical testing and method validation. By utilizing these characterized reference materials, researchers and quality control scientists can ensure accurate impurity profiling, precise quantification of drug substances, and reliable monitoring of degradation pathways. Whether used for method development, preclinical studies, or routine quality control, these reference standards provide the necessary benchmarks to verify purity and maintain compliance with established analytical protocols in drug development programs.